SCHEMBL817869

SCHEMBL817869

C=C[C@H](COc1ccccc1)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.43
LMNA P02545 1/20 0.41
MAOA P21397 1/20 0.38
PTGS1 P23219 1/20 0.38
SCN4A P35499 2/20 0.37
MTNR1A P48039 3/20 0.35
MTNR1B P49286 3/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35
NPC1 O15118 1/20 0.34
MTOR P42345 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CHRNB2 P17787 1/20 0.33
CHRNA7 P36544 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8429746 0.85 CYP2D6 (0.43) CYP2D6LMNAMAOAPTGS1SCN4A
SCHEMBL714416 0.85 CYP2D6 (0.43) CYP2D6LMNAMAOAPTGS1SCN4A
SCHEMBL6490888 0.85 CYP2D6 (0.43) CYP2D6LMNAMAOAPTGS1SCN4A
SCHEMBL18022070 0.85 ADRB2 (0.41) ADRB2ADRB1TP53MAPK1HSD17B10
SCHEMBL16613943 0.84 CASR (0.39) LMNAMAPK1
SCHEMBL3149002 0.82 LMNA (0.42) LMNAHSD17B10
SCHEMBL817473 0.82 LMNA (0.42) LMNAHSD17B10
SCHEMBL31283498 0.80 SMYD2 (0.32) CYP3A4
SCHEMBL6507499 0.80 LMNA (0.49) CYP2D6LMNAMAOAPTGS1SCN4A
SCHEMBL6444947 0.78 MMP13 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897795-B2 Process for the preparation of prostaglandin analogues and intermediates thereof SCINOPHARM TAIWAN LTD. (TW) 2011-03-01 US disclosed
US-20090259058-A1 Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof SCINOPHARM TAIWAN LTD. 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259058-A1 Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof PTGIS, PTGES, PTGER1 CYP2D6 57/4885LMNA 726/4885MAOA 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.